Osteopontin regulates human glioma cell invasiveness and tumor growth in mice

Neuro-Oncology

Volumn 12, Issue 1, 2010, Pages 58-70

  Jan, Hsun Jin ^a   Lee, Chin Cheng ^b   Shih, Yung Luen ^b   Hueng, Dueng Yuan ^c   Ma, Hsin I ^c   Lai, Jing Huei ^a   Wei, Hen Wei ^d   Lee, Horng Mo ^a,e  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b Shin Kong Memorial Hospital   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e Central Taiwan University of Sciences and Technology   (Taiwan)

Author keywords

5 Aza 2' deoxycytidine; Glioma; Invasion; MMP 2; Osteopontin

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GELATINASE A; GLIAL FIBRILLARY ACIDIC PROTEIN; OSTEOPONTIN; SHORT HAIRPIN RNA; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN; CANCER INHIBITION; CANCER INVASION; CELL VIABILITY; CHICK EMBRYO; CONTROLLED STUDY; DISEASE ASSOCIATION; EMBRYO; ENZYME RELEASE; ENZYME SYNTHESIS; GLIOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; AZACITIDINE; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; OSTEOPONTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIMENTIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 75749153239     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop013     Document Type: Article

References (40)

1. Gunther W, Skaftnesmo KO, Arnold H, Terzis AJ. Molecular approaches to brain tumour invasion. Acta Neurochir (Wien). 2003;145:1029-1036.
2. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology. 2005;25:1-7.
3. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64:479-489.
4. Guo Y, Engelhardt M, Wider D, Abdelkarim M, Lubbert M. Effects of 5-aza-2'-deoxycytidine on proliferation, differentiation and p15/ INK4b regulation of human hematopoietic progenitor cells. Leukemia. 2006;20:115-121.
5. Levicar N, Nuttall RK, Lah TT. Proteases in brain tumour progression. Acta Neurochir (Wien). 2003;145:825-838.
6. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer. 2004;90:1877-1881.
7. Chakraborty G, Jain S, Patil TV, Kundu GC. Down-regulation of osteopontin attenuates breast tumor progression in vivo. J Cell Mol Med. 2008;12(6A):2305-2318.
8. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008;68:152-161.
9. Ding Q, Stewart J, Jr, Prince CW, et al. Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res. 2002;62:5336-5343.
10. Takano S, Tsuboi K, Tomono Y, Mitsui Y, Nose T. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer. 2000;82:1967-1973.
11. Said HM, Hagemann C, Staab A, et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol. 2007;83:398-405.
12. Colin C, Baeza N, Bartoli C, et al. Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using suppression subtractive hybridization. Oncogene. 2006;25:2818-2826.
13. Jang T, Sathy B, Hsu YH, et al. A distinct phenotypic change in gliomas at the time of magnetic resonance imaging detection. J Neurosurg. 2008;108:782-790.
14. Denhardt DT, Mistretta D, Chambers AF, et al. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin Exp Metastasis. 2003;20:77-84.
15. Saitoh Y, Kuratsu J, Takeshima H, Yamamoto S, Ushio Y. Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest. 1995;72:55-63.
16. Urquidi V, Sloan D, Kawai K, et al. Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin Cancer Res. 2002;8:61-74.
17. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factorkappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem. 2001;276:44926-44935.
18. Philip S, Kundu GC. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) downregulates these pathways. J Biol Chem. 2003;278:14487-14497.
19. Wai PY, Mi Z, Guo H, et al. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis. 2005;26:741-751.
20. Alonso SR, Tracey L, Ortiz P, et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res. 2007;67:3450-3460.
21. Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res. 2005;65:5996-6000; discussion 6000-5991.
22. Dehghani F, SchachenmayrW, Laun A, KorfHW. Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol. 1998;95:493-504.
23. Mahesparan R, Read TA, Lund-Johansen M, Skaftnesmo KO, Bjerkvig R, Engebraaten O. Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathol. 2003;105:49-57.
24. Rutka JT, Ivanchuk S, Mondal S, et al. Co-expression of nestin and vimentin intermediate filaments in invasive human astrocytoma cells. Int J Dev Neurosci. 1999;17:503-515.
25. Trog D, Fountoulakis M, Friedlein A, Golubnitschaja O. Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions. Proteomics. 2006;6:2924-2930.
26. Jung CS, Foerch C, Schanzer A, et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain. 2007;130:3336-3341.
27. Schmelz K, Sattler N, Wagner M, Lubbert M, Dorken B, Tamm I. Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation- dependent and -independent mechanisms. Leukemia. 2005;19:103-111.
28. Schmelz K, Wagner M, Dorken B, Tamm I. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer. 2005;114:683-695.
29. Waha A, Koch A, Hartmann W, et al. SGNE1/7B2 is epigenetically altered and transcriptionally downregulated in human medulloblastomas. Oncogene. 2007;26:5662-5668.
30. Eramo A, Pallini R, Lotti F, et al. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res. 2005;65:11469-11477.
31. Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell. 1998;94:353-362.
32. Ma HI, Guo P, Li J, et al. Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin. Cancer Res. 2002;62:756-763.
33. Ma HI, Lin SZ, Chiang YH, et al. Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. Gene Ther. 2002;9:2-11.
34. Rahnama F, Shafiei F, Gluckman PD, Mitchell MD, Lobie PE. Epigenetic regulation of human trophoblastic cell migration and invasion. Endocrinology. 2006;147:5275-5283.
35. Chabot GG, Rivard GE, Momparler RL. Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. Cancer Res. 1983;43:592-597.
36. Jang T, Savarese T, Low HP, et al. Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea. Am J Pathol. 2006;168:1676-1685.
37. Koul D, Parthasarathy R, Shen R, et al. Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene. 2001;20:6669-6678.
38. Oki Y, Issa JP. Review: recent clinical trials in epigenetic therapy. Rev Recent Clin Trials. 2006;1:169-182.
39. Zhu WG, Hileman T, Ke Y, et al. 5-Aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem. 2004;279:15161-15166.
40. Fu WN, Bertoni F, Kelsey SM, et al. Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene. 2003;22:451-455.